Previous studies showed that LMNB1 was overexpressed in pancreatic cancer, liver cancer and prostate cancer (Butin-Israeli et al., 2012; Irianto et al., 2016) and its overexpression was associated with poor clinical outcomes in the cervical (Yang et al., 2019) and colon (Izdebska et al., 2018) cancers. Here, LMNB1 is linked to Familial prostate cancer.